Athersys tanks as its stem cell therapy flunks a Phase II stroke trial – FierceBiotech
Channel News Asia |
Athersys tanks as its stem cell therapy flunks a Phase II stroke trial
FierceBiotech Athersys' ($ATHX) in-development stem cell treatment failed to beat placebo in a Phase II trial on stroke patients, demolishing the company's value as management digs for a positive spin. The company's treatment, called MultiStem, is meant to reverse … Athersys' stroke clinical trial yields disappointing results |
